Segments - Global Bacillus Subtilis Market by Forms, (Liquid, Powder, and Paste) by Product Types, (<100 billion CFU/g, 100–300 billion CFU/g, > 300 billion CFU/g), by End Use Industry (Pharmaceutical Industry, Food & Beverage Industry, Agriculture Industry, Livestock Industry, and Others), and by Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2020 – 2027
The global bacillus subtilis market was valued at USD 71.2 Million in 2019 and is projected to reach USD 125.9 Million by 2027, expanding at a CAGR of 7.8% during the forecast period. Bacillus subtilis is a fast-growing gram-positive aerobic bacterium and is found in soil and water. The rod-shaped cells are usually 2–6 µm in length and slightly less than 1 µm in diameter.
The optimal growth temperature is between 30-35°C and the doubling time is only 20 minutes. Under certain growth conditions, cells tend to form long chains, which are connected by unbroken wall material. Under starvation conditions, cells undergo a complex process of cell differentiation, leading to the formation of endospores, which are released through cell membrane lysis, stem cell.
Vegetative cells are mobile. They form biofilms and "fruiting bodies" of spores. Bacillus subtilis releases a variety of enzymes to break down various substrates and enables bacteria to survive in a constantly changing environment. B. subtilis has a long history and was first described in the 19th century. This bacterium was originally called Vibrio subtilis and discovered in 1835 by Christian Gottfried Ehrenberg.
It is first described in detail and renamed in 1872 by Ferdinand Cohn. This bacterium is now known as Bacillus subtilis. Experiments in the late 1950s confirmed its position in the history of genetics and experiments showed that it used linear DNA for natural transformation.
Bacteriocin from Bacillus subtilis inhibits the growth of various pathogens. Bacillus subtilis reduces the incidence of respiratory infections in the elderly. Bacillus subtilis, isolated from soil, shows antibacterial activity against pathogenic human Candida albicans.
Metabolites of bacillus subtilis reduce the resistance of pathogenic urogenital tract microbiota to antibiotics in patients with urinary tract infections, thereby speeding up their recovery. It reduces the symptoms of clostridium difficile infection in mice.
B. subtilis inhibits infection and enteropathy in suckling mice infected with C. rodentium. Hence, the benefits of bacillus subtills in combating infections in humans and animals is driving the market during the forecast period.
Bacillus subtilis has protective and anti-oxidant activity against DNA. A signal molecule from Bacillus subtilis induces the heat shock protein, Hsp27 in mammalian cells, which protects intestinal cells from oxidant-mediated tissue damage and loss of barrier function.
Anti-oxidant properties benefit humans undergoing stress-related activities. Hence, increasing demand for bacillus subtilis, due to its anti-oxidant properties, is driving the market during the forecast period.
Various beneficial properties are associated with bacillus subtilis, which have a positive impact on humans, animals, and plants. It helps in reducing stress levels, increases immunity, improves liver disorders, and reduces the risk of cancer in humans. It helps in preventing nausea, vomiting, abdominal pain, and diarrhea.
Most people do not know about these benefits, which reduces the demand for B. subtilis and adversely affects the sales. Hence, lack of consumer awareness about bacillus subtilis hampers the market growth during the forecast period.
Companies are adopting various strategies to gain competitive advantages. Key players are focusing on product development, which increases the demand for bacillus subtilis. BASF SE launched a new product range, named Velondis, which is a biofungicide seed treatment agent, which was registered with the US Environmental Protection Agency (EPA) in January 2018.
Velondis incorporates a unique stain of Bacillus subtilis, which protects seedlings and plants from soil-borne diseases. Deerland Enzymes, Inc. introduced a new, more soluble probiotic strain, Bacillus subtilis DE111. This spore-forming probiotic is easily soluble in natural foods and used in hot beverages, functional drinks, and dietary supplements.
Bacillus subtilis has multiple health benefits for humans, animals, and plants and thus it is an attractive probiotic species for various clinical conditions. It is used as an important ingredient in many industries such as pharmaceutical, food & beverage, livestock, wastewater management, agriculture, and industrial chemical.
Governments around the globe have issued various rules and regulations for the registration, production, and use of bacillus subtilis. For production various precautionary measures are adopted to reduce the risk of adverse effects on the workers. Bacillus subtilis strains are used as antigen that carry bacterial vaccines and cells to produce antigens.
Based on forms, the global bacillus subtilis market is divided into liquid, powder, and paste. Liquid bacillus subtilis is used in the food & beverage industry, the pharmaceutical industry, and the bio-chemical industry. Bacillus subtilis powder is used in the agriculture industry and as cattle feeding. Bacillus subtilis paste is used in the bio-chemical industry.
In terms of product types, the global bacillus subtilis market is classified into <100 billion CFU/g, 100–300 billion CFU/g, and > 300 billion CFU/g. The effectiveness of probiotics is expressed in CFU or colony-forming unit, which is a unit of measurement used in microbiology to estimate the number of bacteria that can divide and form colonies in a sample, although most positive clinical studies indicate a probiotic dose of 10 to 20 billion CFU per day is enough to maintain a healthy digestive system and immunity, and 50 to 100 billion CFU products are becoming more common. Bacillus subtilis products are measured in billion CFU/g.
In terms of End Use Industry, the global bacillus subtilis market is classified into pharmaceutical, food & beverage, agriculture, livestock, and others. The food & beverage industry is expected to hold a significant market share during the forecast period owing to its various health benefits such as improved liver disorder, reduced risk of cancer, protection against infections and allergies, and decreased obesity.
Based on regions, the global bacillus subtilis market is fragmented into North America, Europe, Latin America, and Middle East & Africa. Growing demand for high-purity Bacillus subtilis in countries such as Japan, China, and India have led to the substantial growth of the Bacillus subtilis market in Asia Pacific.
Probiotic beverage formulations containing Bacillus subtilis are popular in South Korea and Japan. Latin America and the Middle East & Africa are expected to hold a significant share of the market during the forecast period.
The demand for Bacillus subtilis is expected to rise in key industries such as pharmaceuticals, food processing, and beverages in these regions. Increasing demand for non-toxic bacterial products and changes in consumer preferences that are estimated to fuel the demand for Bacillus subtilis in the near future.
Key players in the market include Bayer AG, Deerland Probiotics & Enzymes, Inc, THE REAL IPM CO.(KENYA) LTD (BIOBEST GROUP), Aumgene Biosciences, Wuhan Kernel Bio-tech Co., Ltd., Meteoric Biopharmaceuticals Pvt. Ltd., BASF SE, Manidharma Biotech Private Limited, Lonza, AgriLife, Anand Agro Care, and Merck KGaA. These players are considered as key manufacturers of the market based on different varieties of product availability, regional presence, better supply chain management system, and the increasing demand for the products. The players are adopting key strategies such as product development, geographical expansion, mergers and acquisition and many other strategies to increase their demand for global bacillus subtilis market.
Major Manufactures include Bayer AG, Deerland Probiotics & Enzymes, Inc, THE REAL IPM CO.(KENYA) LTD (BIOBEST GROUP), Aumgene Biosciences, Wuhan Kernel Bio-tech Co., Ltd., Meteoric Biopharmaceuticals Pvt. Ltd., BASF SE, Manidharma Biotech Private Limited, Lonza, AgriLife, Anand Agro Care, and Merck KGaA.
The base year considered for the global bacillus subtilis market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years, 2020 is an estimated year and the forecast is provided from 2021 to 2027.
The market is expected to witness growth at a fast pace with increase in terms of demand during 2019-2020 owing to the positive impact of COVID-19 pandemic on the global bacillus subtilis market.
Pharmaceutical, food & beverage, agriculture, livestock, and others are few of the key end use industries driving the market growth.
The global bacillus subtilis market is anticipated to grow significantly during forecast period due beneficial in combating infections, rising demand for bacillus subtilis due to GI traits, increasing demand for bacillus subtilis due to its anti-oxidant properties, and benefits of bacillus subtilis for environment.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
In addition to market size (in USD Million) and Company Market Share (in % for base year 2019), other data such Macro-economic factors, Impact of key regulations on the market, technology trends, and COVID-19 Impact on the global bacillus subtilis market is available in final report.
According to this Growth Market Reports, report, the market from global bacillus subtilis market is likely to register a CAGR of 7.8% during period 2020-2027, with an anticipated valuation of USD 125.9 Mn by the end of the 2027.
Additional company profiles can be provided on request.